Clinical Trial Update: Gene Therapy for Chronic Granulomatous Disease in Korea [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 gene therapy trial for chronic granulomatous disease conducted by Helixmith in Korea has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• Undisclosed gene therapy

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Chronic Granulomatous Disease | Phase 1, Phase 2 | Status: WITHDRAWN